Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 13/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | BLM | P54132 | 1/20 | 0.38 |
| ▸ | MAOB | P27338 | 2/20 | 0.37 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.35 |
| ▸ | PIK3CB | P42338 | 9/20 | 0.35 |
| ▸ | PIK3CG | P48736 | 9/20 | 0.35 |
| ▸ | PIK3CD | O00329 | 7/20 | 0.35 |
| ▸ | PPARA | Q07869 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1119025 | 0.79 | NPY5R (0.47) | PIK3CALMNAMAPTHTTPIK3CB | |
| SCHEMBL1484851 | 0.78 | PIK3CA (0.46) | PIK3CALMNAMAPTHTTBLM | |
| SCHEMBL1516855 | 0.76 | MAPT (0.42) | PIK3CALMNAMAPTHTTBLM | |
| SCHEMBL1484798 | 0.75 | KDM4E (0.48) | PIK3CALMNAMAPTPIK3CBPIK3CG | |
| SCHEMBL1484711 | 0.72 | PIK3CA (0.42) | PIK3CAPIK3CBPIK3CGPIK3CD | |
| SCHEMBL1484686 | 0.72 | PIK3CA (0.42) | PIK3CAPIK3CBPIK3CGPIK3CD | |
| SCHEMBL1484697 | 0.72 | PIK3CA (0.47) | PIK3CAPIK3CBPIK3CGPIK3CD | |
| SCHEMBL988703 | 0.72 | PIK3CA (0.44) | PIK3CAMAPTPIK3CBPIK3CGPIK3CD | |
| SCHEMBL1484954 | 0.72 | PIK3CA (0.42) | PIK3CAPIK3CBPIK3CGPIK3CD | |
| SCHEMBL1042611 | 0.72 | PIK3CA (0.38) | PIK3CAPIK3CBPIK3CGPIK3CD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8846762-B2 | Benzopyran and benzoxepin PI3K inhibitor compounds and methods of use | GENENTECH, INC. (US) | 2014-09-30 | — | — | US | disclosed |
| US-20130123263-A1 | BENZOPYRAN AND BENZOXEPIN PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | F. HOFFMANN - LA ROCHE AG (CH) | 2013-05-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130123263-A1 | BENZOPYRAN AND BENZOXEPIN PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | PIK3CA, BMX, PIK3CD | PIK3CA 1/4885LMNA 645/4885MAPT 1255/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.